PBLA Panbela Therapeutics
- 0.410
- -0.010-2.36%
Panbela Therapeutics News
HC Wainwright & Co. Maintains Buy on Panbela Therapeutics, Lowers Price Target to $5
Panbela Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), Carisma Therapeutics (CARM) and Panbela Therapeutics (OtherPBLA)
Panbela Therapeutics Analyst Ratings
Roth MKM Maintains Buy on Panbela Therapeutics, Maintains $25 Price Target
Watching Panbela Therapeutics; Roth MKM Says "'Ipsen FDA Approval Of Onivyde In Pancreatic Cancer And Panbelas Earlier Phase 1/1b Results For Sbp-101 For The Same Indication Gives Investors Reason For Optimism.' Reiterate Buy And $25 Price Target"
Panbela Therapeutics Analyst Ratings
Roth MKM Reiterates Buy on Panbela Therapeutics, Maintains $25 Price Target
Panbela Therapeutics Analyst Ratings
Positive Outlook for Panbela Therapeutics Backed by Buy Rating and Clinical Progress
Promising Clinical Trials and Strategic Financial Maneuvers Propel Panbela Therapeutics to a 'Buy' Rating: An Analysis by Joseph Pantginis
HC Wainwright & Co. Reiterates Buy on Panbela Therapeutics, Maintains $16 Price Target
Panbela Therapeutics Analyst Ratings
Panbela Therapeutics (PBLA) Receives a Buy From H.C. Wainwright
Panbela Therapeutics Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Panbela Therapeutics (PBLA), Assertio Therapeutics (ASRT)
Panbela Therapeutics (PBLA) Gets a Buy From H.C. Wainwright
H.C. Wainwright Reaffirms Their Buy Rating on Panbela Therapeutics (PBLA)
Panbela Therapeutics (PBLA) Gets a Buy From H.C. Wainwright
HC Wainwright & Co. Reiterates Buy on Panbela Therapeutics, Raises Price Target to $16
Analysis
Price Target
No Data
